Colorectal Cancer Cell Invasion and Functional Properties Depend on Peri-Tumoral Extracellular Matrix.
3D cell cultures
colorectal cancer
doxorubicin
epithelial-to-mesenchymal transition (EMT)
matrigel
matrix metalloproteinases
scanning electron microscopy
type I collagen
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
22 Jun 2023
22 Jun 2023
Historique:
received:
24
05
2023
revised:
16
06
2023
accepted:
19
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
We investigated how the extracellular matrix (ECM) affects LoVo colorectal cancer cells behavior during a spatiotemporal invasion. Epithelial-to-mesenchymal transition (EMT) markers, matrix-degrading enzymes, and morphological phenotypes expressed by LoVo-S (doxorubicin-sensitive) and higher aggressive LoVo-R (doxorubicin-resistant) were evaluated in cells cultured for 3 and 24 h on Millipore filters covered by Matrigel, mimicking the basement membrane, or type I Collagen reproducing a desmoplastic lamina propria. EMT and invasiveness were investigated with RT-qPCR, Western blot, and scanning electron microscopy. As time went by, most gene expressions decreased, but in type I Collagen samples, a strong reduction and high increase in MMP-2 expression in LoVo-S and -R cells occurred, respectively. These data were confirmed by the development of an epithelial morphological phenotype in LoVo-S and invading phenotypes with invadopodia in LoVo-R cells as well as by protein-level analysis. We suggest that the duration of culturing and type of substrate influence the morphological phenotype and aggressiveness of both these cell types differently. In particular, the type I collagen meshwork, consisting of large fibrils confining inter fibrillar micropores, affects the two cell types differently. It attenuates drug-sensitive LoVo-S cell aggressiveness but improves a proteolytic invasion in drug-resistant LoVo-R cells as time goes by. Experimental studies on CRC cells should examine the peri-tumoral ECM components, as well as the dynamic physical conditions of TME, which affect the behavior and aggressiveness of both drug-sensitive and drug-resistant LoVo cells differently.
Identifiants
pubmed: 37509428
pii: biomedicines11071788
doi: 10.3390/biomedicines11071788
pmc: PMC10376217
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Prog Mol Biol Transl Sci. 2014;126:317-52
pubmed: 25081624
Nat Mater. 2023 Jan;22(1):117-127
pubmed: 36456871
BMC Cancer. 2020 Jul 15;20(1):660
pubmed: 32669083
Cells. 2020 Sep 04;9(9):
pubmed: 32899718
Diagnostics (Basel). 2021 Mar 09;11(3):
pubmed: 33803206
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Sci Rep. 2015 Nov 13;5:16538
pubmed: 26563869
Front Bioeng Biotechnol. 2020 Nov 20;8:596599
pubmed: 33330427
FEBS Lett. 2022 Mar;596(5):638-654
pubmed: 34787896
PLoS One. 2012;7(3):e33476
pubmed: 22479403
Exp Ther Med. 2018 Apr;15(4):3751-3758
pubmed: 29581735
J Hematol Oncol. 2022 Mar 24;15(1):34
pubmed: 35331296
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Bioengineering (Basel). 2023 Jan 19;10(2):
pubmed: 36829629
Int J Colorectal Dis. 2005 May;20(3):245-52
pubmed: 15592677
Eur J Med Chem. 2017 Feb 15;127:577-585
pubmed: 28109950
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Sci Rep. 2020 Aug 6;10(1):13254
pubmed: 32764590
Cell. 2013 Dec 19;155(7):1639-51
pubmed: 24332913
J Exp Clin Cancer Res. 2022 Sep 16;41(1):276
pubmed: 36114508
Cell. 2018 Feb 8;172(4):841-856.e16
pubmed: 29395328
Int J Cancer. 2003 Nov 20;107(4):541-50
pubmed: 14520690
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nature. 2022 Nov;611(7935):365-373
pubmed: 36323783
FEBS J. 2021 Dec;288(24):6850-6912
pubmed: 33605520
Int J Mol Sci. 2021 Aug 31;22(17):
pubmed: 34502361
J Clin Med. 2019 Feb 07;8(2):
pubmed: 30736469
Biomolecules. 2022 Nov 30;12(12):
pubmed: 36551219
Oncol Lett. 2017 Nov;14(5):5865-5870
pubmed: 29113219
Front Mol Biosci. 2022 Apr 26;9:864302
pubmed: 35558554
Oncogene. 2018 Aug;37(35):4769-4780
pubmed: 29780167
BMC Cancer. 2021 Feb 10;21(1):149
pubmed: 33568081
Stem Cell Rev Rep. 2015 Oct;11(5):710-27
pubmed: 26085192
Gut. 2022 Sep;71(9):1843-1855
pubmed: 34921062
J Transl Med. 2019 Sep 14;17(1):309
pubmed: 31521169
Dev Dyn. 2007 Jun;236(6):1683-93
pubmed: 17440987
Cancer Cell Int. 2010 Aug 13;10:26
pubmed: 20707917
Gels. 2022 Sep 07;8(9):
pubmed: 36135279
Curr Opin Cell Biol. 2010 Oct;22(5):697-706
pubmed: 20822891
Nat Phys. 2022 Sep;18(9):1112-1121
pubmed: 37220497
Int J Mol Sci. 2018 Sep 20;19(10):
pubmed: 30241395
Am J Pathol. 2011 Mar;178(3):1221-32
pubmed: 21356373
BMC Med. 2021 Nov 18;19(1):273
pubmed: 34789257
BMC Mol Cell Biol. 2022 Jan 3;23(1):1
pubmed: 34979904
J Biol Chem. 1995 Mar 17;270(11):5872-6
pubmed: 7890717
Sci Rep. 2017 Nov 2;7(1):14956
pubmed: 29097791
Sci Adv. 2019 Jul 24;5(7):eaaw7243
pubmed: 31355337
Science. 2016 Apr 8;352(6282):167-9
pubmed: 27124449
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
Matrix Biol. 2017 Dec;64:6-16
pubmed: 28389162
Eur J Cell Biol. 2022 Apr;101(2):151220
pubmed: 35366585
Biophys J. 2014 Dec 2;107(11):2546-58
pubmed: 25468334
Front Cell Dev Biol. 2015 Feb 02;3:4
pubmed: 25699257
Br J Cancer. 2008 Jun 3;98(11):1820-3
pubmed: 18506186
Clin Cancer Res. 2015 Aug 1;21(15):3561-8
pubmed: 25695692
Transl Oncol. 2021 Jan;14(1):100899
pubmed: 33080522
Oncotarget. 2020 Sep 22;11(38):3486-3488
pubmed: 33014284